Table 2.
Baseline characteristics of patients, overall and by study group.
| Patient characteristics | All participants (N=1449) | Intervention group (n=734) | Control group (n=715) | |
| Sex, n (%) | ||||
|
|
Male | 812 (56) | 402 (54.8) | 410 (57.3) |
|
|
Female | 637 (44) | 332 (45.2) | 305 (42.7) |
| Age (years), mean (SD) | 65.9 (12.1) | 66.3 (11.3) | 65.4 (12.9) | |
| Prescribed ACEIa or ARBb , n (%) | ||||
|
|
ACEI only | 215 (14.8) | 109 (14.9) | 106 (14.8) |
|
|
ARB only | 321 (22.2) | 166 (22.6) | 155 (21.7) |
|
|
ACEI and ARB | 6 (0.4) | 4 (0.6) | 2 (0.3) |
|
|
None | 907 (62.6) | 455 (62) | 452 (63.2) |
| Prescribed statins, n (%) | ||||
|
|
Yes | 424 (29.3) | 192 (26.2) | 232 (32.5) |
|
|
No | 1025 (70.7) | 542 (73.8) | 483 (67.5) |
| Guideline recommended initiation, n (%) | ||||
|
|
Both ACEI or ARB and statins | 246 (17) | 131 (17.9) | 115 (16.1) |
|
|
ACEI or ARBs only | 554 (38.2) | 264 (36) | 290 (40.5) |
|
|
Statin only | 649 (44.8) | 339 (46.2) | 310 (43.4) |
| Cardiovascular disease risk category, n (%) | ||||
|
|
Total sample | 1065 (73.5) | 539 (73.4) | 526 (73.8) |
|
|
Low | 85 (8) | 43 (7.6) | 42 (8) |
|
|
Moderate | 29 (2.7) | 14 (2.7) | 15 (2.9) |
|
|
High | 951 (89.3) | 482 (89.7) | 469 (89.2) |
| Type 2 diabetes n (%) | 633 (43.7) | 308 (42) | 325 (45.5) | |
| Systolic blood pressure (mmHg) | ||||
|
|
Number (%) | 843 (58.2) | 434 (59.1) | 409 (57.2) |
|
|
Mean (SD) | 138 (20) | 138 (20) | 137 (19) |
| Lipids (all mmol/L) | ||||
|
|
Total cholesterol, n (%) | 916 (63.2) | 465 (63.4) | 451 (63.1) |
|
|
Total cholesterol, mean (SD) | 4.8 (1.2) | 4.8 (1.2) | 4.8 (1.3) |
|
|
Low-density lipoproteins, n (%) | 844 (58.2) | 431 (58.7) | 413 (57.8) |
|
|
Low-density lipoproteins, mean (SD) | 2.7 (1.1) | 2.7 (1.1) | 2.6 (1.1) |
|
|
High-density lipoproteins, n (%) | 865 (59.7) | 444 (60.5) | 421 (58.9) |
|
|
High-density lipoproteins, mean (SD) | 1.3 (0.4) | 1.3 (0.4) | 1.3 (0.4) |
|
|
Triglycerides, n (%) | 914 (63.1) | 464 (63.2) | 450 (62.9) |
|
|
Triglycerides mean (SD) | 2.1 (1.8) | 2.0 (1.4) | 2.1 (2.1) |
| Urine albumin-creatinine ratio (mg/mmol)c | ||||
|
|
Number (%) | 702 (48.4) | 323 (44) | 379 (53) |
|
|
Median (IQR)c | 5.5 (1.6-21.7) | 5.2 (1.4-22.5) | 5.6 (1.7-20.2) |
|
|
Macroalbuminuria, n (%) | 137 (19.5) | 64 (19.8) | 73 (19.3) |
|
|
Microalbuminuria, n (%) | 343 (48.9) | 150 (46.4) | 193 (50.9) |
|
|
Normal, n (%) | 222 (31.6) | 109 (33.8) | 113 (29.8) |
| Estimated glomerular filtration rate (mL/min/1.73m2) | ||||
|
|
Number (%) | 1175 (81.1) | 592 (80.7) | 583 (81.5) |
|
|
Mean (SD) | 55.3 (20.9) | 53.5 (20.4) | 57.1 (21.2) |
|
|
G1 (≥90), n (%) | 149 (12.7) | 61 (10.3) | 98 (15.1) |
|
|
G2 (60-89), n (%) | 224 (19.1) | 105 (17.7) | 119 (20.4) |
|
|
G3a (45-59), n (%) | 428 (36.4) | 221 (37.3) | 207 (35.5) |
|
|
G3b (30-44), n (%) | 267 (22.7) | 146 (24.7) | 121 (20.8) |
|
|
G4 (15-29), n (%) | 73 (6.2) | 37 (6.3) | 36 (6.2) |
|
|
G5 (<15), n (%) | 35 (2.9) | 22 (3.7) | 12 (2.1) |
aACEI: angiotensin-converting enzyme inhibitor.
bARB: angiotensin receptor blocker.
cMedian and IQR were reported due to skewed distribution.